On October 29, 2024 Delta-Fly Pharma reported its latest development status (Press release, Delta-Fly Pharma, OCT 29, 2024, View Source [SID1234647509]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Patient enrollment is progressing well in the Phase I trial of the Phase I/II study of DFP-10917 in combination with venetoclax in patients with AML (acute myeloid leukemia) previously treated with venetoclax monotherapy. The first three patients are showing encouraging safety and efficacy results, suggesting promising development.

The existing standard combination chemotherapy for AML patients is azacitidine plus venetoclax, but it is not comfortable for AML patients. We are trying to combine DFP-10917 with venetoclax as a safer alternative treatment for AML with objective approval of NDA (New Drug Application) from the US FDA, in a possible collaboration with a global mega-pharma company.

The Phase III study of DFP-10917 in patients with relapsed or chemoresistant AML is expected to reach a data threshold as the number of long-term survivors has declined since then.

After learning about our innovative approach to treating cancer patients without a satisfactory therapeutic solution, do not hesitate to contact us.

The text of the press release resulting from a translation should in no way be considered official. The only version of the press release that is authoritative is that of the press release in its original language. The translation must always be compared with the source text, which will constitute precedent.